chronic lymphocytic leukaemia

News

Lilly's BTK drug Jaypirca joins first-line options in US

Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA for its first frontline indication, but will it be reserved for later-line use?

News

Lilly trumpets strong result for Jaypirca in CLL at EHA

New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.

News

Roche doubles down on BTK with $2.3bn Nurix deal

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

Jazz and Lilly cancer drugs cleared for use by NHS

Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.

Lilly's BTK drug Jaypirca joins first-line options in US

Lilly trumpets strong result for Jaypirca in CLL at EHA

Roche doubles down on BTK with $2.3bn Nurix deal

Jazz and Lilly cancer drugs cleared for use by NHS

FDA clears first all-oral combo for first-line CLL treatment

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

chronic lymphocytic leukaemia

Editor's Picks